Experimental models of acute renal failure and erythropoietin: What evidence of a direct effect?

Renal Failure

Volumn 29, Issue 3, 2007, Pages 379-386

  Sturiale, Alessio ^a   Campo, Susanna ^a   Crascì, Eleonora ^a   Aloisi, Carmela ^a   Buemi, Michele ^a,b  

^a UNIVERSITY OF MESSINA   (Italy)

^b NONE   (Italy)

Author keywords

Apoptosis; Erythropoietin; JAK; Renal failure; STAT

Indexed keywords

ERYTHROPOIETIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; JANUS KINASE; KI 67 ANTIGEN; STAT PROTEIN; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN; VASCULOTROPIN;

ACUTE KIDNEY FAILURE; CELL DIFFERENTIATION; CELL REGENERATION; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; ERYTHROPOIESIS; HUMAN; KIDNEY FUNCTION; KIDNEY TUBULE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; STEM CELL MOBILIZATION;

ANIMALS; CELL DIFFERENTIATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN, RECOMBINANT; HUMANS; ISCHEMIA; KIDNEY; KIDNEY FAILURE, ACUTE; SIGNAL TRANSDUCTION;

EID: 34248547563     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220701193290     Document Type: Review

References (84)

1. Witzgall R, Brown D, Schwarz C, Bonventre JV. Localization of proliferating cell nuclear antigen, vimentin, c-Fos, and clusterin in the postischemic kidney. Evidence for a heterogenous genetic response among nephron segments, and a large pool of mitotically active and dedifferentiated cells. J Clin Invest. 1994 May; 93(5):2175-2188.
2. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N. Engl. J. Med. 1996;334:1448-1460.
3. Zuk A, Bonventre JV, Brown D, Matlin KS. Polarity, integrin, and extracellular matrix dynamics in the postischemic rat kidney. Am J Physiol. 1998 Sep;275(3 Pt 1):C711-C731.
4. Fujigaki Y, Goto T, Sakakima M, Fukasawa H, Miyaji T, Yamamoto T, Hishida A. Kinetics and characterization of initially regenerating proximal tubules in S3 segment in response to various degrees of acute tubular injury. Nephrol Dial Transplant. 2006 Jan;21(1):41-45.
5. Maeshima A, Yamashita S, Nojima Y. Identification of renal progenitor-like tubular cells that participate in the regeneration processes of the kidney. J Am Soc Nephrol. 2003;14:3138-3146.
6. De Celle T, Cleutjens JP, Blankesteijn WM, Debets JJ, Smits JF, Janssen BJ. Long-term structural and functional consequences of cardiac ischemia-reperfusion injury in vivo in mice. Exp Physiol. 2004 Sep;89(5):605-15. [E-pub 2004 Jul 15.]
7. De Celle T, Vanrobaeys F, Lijnen P, Matthijs Blankesteijn W, Heeneman S, Van Beeumen J, Devreese B, Jos F, Smits M, Janssen BJA. Alterations in mouse cardiac proteome after in vivo myocardial infarction: permanent ischaemia versus ischaemia-reperfusion. Experimental Physiology. 2005;90(4):593-606.
8. Chen Z, Chua CC, Gao J, Hamdy RC, Chua BH. Protective effect of melatonin on myocardial infarction. Am J Physiol. 2003;284:H1618-H1624.
9. Orlic D, et al. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc. Natl. Acad. Sci. USA. 2001;98:10344-10349.
10. Paczynski RP, Venkatesan R, Diringer MN, He YY, Hsu CY, Lin W. Effects of fluid management on edema volume and midline shift in a rat model of ischemic stroke. Stroke. 2000;31(7):1702-1708.
11. Van Lookeren Campagne M, Thibodeaux H, van Bruggen N, Cairns B, Gerlai R, Palmer JT, Williams SP, Lowe DG. Evidence for a protective role of metallothionein-1 in focal cerebral ischemia. Proc Natl Acad Sci USA. 1999 Oct 26;96(22):12870-12875.
12. Yang B, Jain S, Pawluczyk IZ, Imtiaz S, Bowley L, Ashra SY, Nicholson ML. Inflammation and caspase activation in long-term renal ischemia/reperfusion injury and immunosuppression in rats. Kidney Int. 2005 Nov;68(5):2050-2067.
13. Hayashi K, Wakino S, Kanda T, Homma K, Sugano N, Saruta T. Molecular mechanisms and therapeutic strategies of chronic renal injury: role of rho-kinase in the development of renal injury. J Pharmacol Sci. 2006 Jan;100(1):29-33. [E-pub 2006 Jan 6.]
14. Docherty NG, O'Sullivan OE, Healy DA, Fitzpatrick JM, Watson RW. Evidence that inhibition of tubular cell apoptosis protects against renal damage and development of fibrosis following ureteric obstruction. Am J Physiol Renal Physiol. 2006 Jan;290(1):F4-F13.
15. Rodriguez-Iturbe B, Johnson RJ, Herrera-Acosta J. Tubulointerstitial damage and progression of renal failure. Kidney Int Suppl. 2005 Dec;99:S82-S86.
16. Li P, Akimoto T, Zhang M, Williams RS, Yan Z. Resident stem cells are not required for exercise-induced fiber type-switching and angiogenesis, but required for activity-dependent muscle growth. Am J Physiol Cell Physiol. 2006 Jun;290(6):C1461-C1468.
17. Negroni E, Butler-Browne GS, Mouly V. Myogenic stem cells: regeneration and cell therapy in human skeletal muscle. Pathol Biol (Paris). 2006 Mar;54(2):100-108. [E-pub 2005 Oct 21.]
18. Yano T, Miura T, Ikeda Y, Matsuda E, Saito K, Miki T, Kobayashi H, Nishino Y, Ohtani S, Shimamoto K. Intracardiac fibroblasts, but not bone marrow derived cells, are the origin of myofibroblasts in myocardial infarct repair. Cardiovasc Pathol. 2005 Sep-Oct;14(5):241-246.
19. Bull ND, Bartlett PF. The adult mouse hippocampal progenitor is neurogenic but not a stem cell. J Neurosci. 2005 Nov 23;25(47):10815- 10821.
20. Ladeby R, Wirenfeldt M, Garcia-Ovejero D, Fenger C, Dissing-Olesen L, Dalmau I, Finsen B. Microglial cell population dynamics in the injured adult central nervous system. Brain Res Brain Res Rev. 2005 Apr;48(2):196-206.
21. Krause DS, et al. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell. 2001;105:369-377.
22. Bussolati B, Bruno S, Grange C, Buttiglieri S, Deregibus MC, Cantino D, Camussi G. Isolation of renal progenitor cells from adult human kidney. Am J Pathol. 2005 Feb;166(2):545-555.
23. Lin F, et al. Hematopoietic stem cells contribute to the regeneration of renal tubules after renal ischemia-reperfusion injury in mice. J Am Soc Nephrol. 2003;141188-1199. See
24. also: Kale S, et al. Bone marrow stem cells contribute to repair of the ischemically injured renal tubule. J Clin Invest. 2003;112:42-49.
25. Witzgall R, Obermuller N, Bolitz U, Calvet JP, Cowley BD Jr, Walker C, Kriz W, Gretz N, Bonventre JV. Kid-1 expression is high in differentiated renal proximal tubule cells and suppressed in cyst epithelia. Am J Physiol. 1998 Dec;275(6 Pt 2):F928-F937.
26. Duffield JS, Park KM, Hsiao LL, Kelley VR, Scadden DT, Ichimura T, Bonventre JV. Restoration of tubular epithelial cells during repair of the postischemic kidney occurs independently of bone marrow-derived stem cells. J Clin Invest. 2005 Jul;115(7):1743-1755. [E-pub 2005 Jun 2.]
27. Lin F, et al. Intrarenal cells, not bone marrow-derived cells, are the major source for regeneration in postischemic kidney. Journal Clinic Invest. 2005;115:1756-1764.
28. Fink JC, et al. Use of erythropoietin before the initiation of dialysis and its impact on mortalità. Am. J Kidney Dis. 2001;37:348-355.
29. Also see: Valderràbano F, et al. Pre-dialisys survey on anaemia management. Nephrol Dial Transplant 2003;18:89-100.
30. Theodoridis M, Passadakis P, Kriki P, Panagoutsos S, Yannatos E, Kantartzi K, Sivridis D, Vargemezis V. Efficient monthly subcutaneous administration of darbepoetin in stable CAPD patients. Perit Dial Int. 2005 Nov-Dec;25(6):564-569.
31. Hayashi T, et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am. J. Kidney Dis. 2000;35:250-256.
32. See also: Portolès J, et al. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am. J. Kidney Dis. 1997;29:541-548.
33. Moreno F., et al. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. J Am Soc. Nephrology. 2000;11:335-342.
34. Kirkpatrick JP, Hardee ME, Snyder SA, Peltz CM, Zhao Y, Brizel DM, Dewhirst MW, Blackwell KL. The effect of darbepoetin alfa on growth, oxygenation and radioresponsiveness of a breast adenocarcinoma. Radiat Res. 2006 Feb;165(2):192-201.
35. Cersosimo RJ, Jacobson DR. EPOetin alfa versus darbepoetin alfa in hemotherapy-related anemia. Ann Pharmacother. 2006 Jan;40(1):58-65, quiz 169-170. [E-pub 2005 Dec 6.]
36. Waltzman R, Croot C, Justice GR, Fesen MR, Charu V, Williams D. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist. 2005 Sep;10(8):642-650.
37. Smith RE Jr. Erythropoietic agents in the management of cancer patients. Part 1: Anemia, quality of life, and possible effects on survival. J Support Oncol. 2003 Nov-Dec;1(4):249-259.
38. Evens AM, Bennett CL, Luminari S. EPOetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group. Best Pract Res Clin Haematol. 2005;18(3):481-489.
39. Hardee ME. Erythropoietin biology in cancer. Clin Cancer Res. 2006 Jan 15;12(2):332-339.
40. Acs G, et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res. 2001;61: 3561-3565.
41. Leyland Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 2003;4:459-460.
42. Jungers P, et al. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant. 2001;16:307-312.
43. Fliser D, Bahlmann FH, Haller H. EPO: renoprotection beyond anemia correction. Pediatr Nephrol. [E-pub 2006 Sep 7].
44. Vesey DA, et al. Erythropoietin protects against ischemic acute renal injury. Nephrol Dial Transplant. 2004;19:348-355.
45. Sharples EJ, et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol. 2004;15:2115-2124.
46. Bagnis C, Beauls H, et al. Erythropoietin enhances recovery after cisplatin-induced acute renal failure in the rat. Nephrol Dial Transplant. 2001;16:932-938.
47. Rossert J, et al. EPOetin treatment: what are the arguments to expect a beneficial effect on renal disease progression? Nephrol Dial Transplant. 2002;17:359-361.
48. Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int. 55:808-820, 1999.
49. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, Thompson RB, Petrofski JA, Annex BH, Stamler JS, Koch WJ. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest. 2003 Oct;112(7):999-1007.
50. Calvillo L, Latini R, Kajstura J, et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA. 2003;100:4802-4806.
51. Sakanaka M, Wen TC, Matsuda S, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA. 1998;95:4635-4640.
52. Siren AL, Fratelli M, Brines M, et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA. 2001;98:4044-4049.
53. Moonkyoung UM, et al. Anti apoptotic effects of erythropoietin in differentiated neuroblastoma SH-SY5Y cells require activation of both the STAT5 and AKT signaling pathways. J Biol Chem. 2006;281(9):5648-5656.
54. Darnell Jr JE. Reflections on STAT3, STAT5, and STAT6 as fat STATs. PNAS. 1996 Jun 25;93(13):6221-6224.
55. Silva M, Benito A, Sanz C, Prosper F, Ekhterae D, Nunez G, Fernandez-Luna JL. Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines. J Biol Chem. 1999 Aug 6;274(32):22165-22169.
56. Arcasoy MO, Jiang X. Co-operative signalling mechanisms required for erythroid precursor expansion in response to erythropoietin and stem cell factor. Br J Haematol. 2005 Jul;130(1):121-129.
57. Zeuner A, Pedini F, Signore M, Testa U, Pelosi E, Peschle C, De Maria R. Stem cell factor protects erythroid precursor cells from chemotherapeutic agents via up-regulation of BCL-2 family proteins. Blood. 2003 Jul 1;102(1):87-93. [E-pub 2003 Mar 13.]
58. Dolznig H, Habermann B, Stangl K, Deiner EM, Moriggl R, Beug H, Mullner EW. Apoptosis protection by the EPO target Bcl-X(L) allows factor-independent differentiation of primary erythroblasts. Curr Biol. 2002 Jul 9;12(13):1076-1085.
59. Stuart S., et al. Regulation of expression of the human erythropoietin receptor gene. Blood Cells, Molecule, and Diseases. 1996 Sep 30; 22(18):;30:214-224.
60. Geijsen N, Koenderman L, Coffer PJ. Specificity in cytokine signal transduction: lessons learned from the IL-3/IL-5/GM-CSF receptor family. Cytokine and Growth Factor Reviews. 2001;1219-25.
61. Brizzi MF, Avanzi GC, Pegoraro L. Hematopoietic growth factor receptors. Int J Cell Cloning. 1991 Jul;9(4):274-300.
62. Jubinsky PT, Krijanovski OI, Nathan DG, Tavernier J, Sieff CA. The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor. Blood. 1997 Sep 1;90(5):1867-1873.
63. Halupa A, Bailey ML, Huang K, Iscove NN, Levy DE, Barber DL. A novel role for STAT1 in regulating murine erythropoiesis: deletion of STAT1 results in overall reduction of erythroid progenitors and alters their distribution. Blood. 2005 Jan 15;105(2):552-561. [E-pub 2004 Jun 22.]
64. Kirito K, Uchida M, Yamada M, Miura Y, Komatsu N. A distinct function of STAT proteins in erythropoietin signal transduction. J Biol Chem. 1997 Jun 27;272(26):16507-16513.
65. Nemoto T, Yokota N, Keane WF, Rabb H. Recombinant erythropoietin rapidly treats anemia in ischemic acute renal failure. Kidney Int. 2001 Jan;59(1):246-251.
66. Vesey DA, Cheung C, Pat B, Endre Z, Gobe G, Johnson DW. Erythropoietin protects against ischemic acute renal injury. Nephrol Dial Transplant. 2004 Feb;19(2):348-355.
67. Rafiee P, Shi Y, Su J, Pritchard KA Jr, Tweddell JS, Baker JE. Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways. Basic Res Cardiol. 2005 May;100(3):187-197. [E-pub 2004 Dec 22.]
68. Nishihara M, Miura T, Miki T, Sakamoto J, Tanno M, Kobayashi H, Ikeda Y, Ohori K, Takahashi A, Shimamoto K. Erythropoietin affords additional cardioprotection to preconditioned hearts by enhanced phosphorylation of glycogen synthase kinase-3{beta} Am J Physiol Heart Circ Physiol. 2006 Aug;291(2):H748-H755.
69. Lee ST, Chu K, Sinn DI, Jung KH, Kim EH, Kim SJ, Kim JM, Ko SY, Kim M, Roh JK. Erythropoietin reduces perihematomal inflammation and cell death with eNOS and STAT3 activations in experimental intracerebral hemorrhage. J Neurochem. 2006 Mar;96(6):1728-1739.
70. Kretz A, Happold CJ, Marticke JK, Isenmann S. Erythropoietin promotes regeneration of adult CNS neurons via Jak2/Stat3 and PI3K/AKT pathway activation. Mol Cell Neurosci. 2005 Aug;29(4):569-579.
71. Barber DL, D'Andrea AD. Erythropoietin and interleukin-2 activate distinct JAK kinase family members. Mol Cell Biol. 1994 Oct;14(10):6506-6514.
72. Millot GA, Svinarchuk F, Lacout C, Vainchenker W, Dumenil D. The granulocyte colony-stimulating factor receptor supports erythroid differentiation in the absence of the erythropoietin receptor or Stat5. Br J Haematol. 2001 Feb;112(2):449-458.
73. Filip S, Vanasek J, Blaha M, Mericka P, Vavrova J, Podzimek K. The increase of the rate of hemopoietic recovery and clinical benefit of the erythropoietin (EPO) and granulocyte colony-stimulating factor (G-CSF) with peripheral blood progenitor cells (PBPC) after intensive cyclic chemotherapy in high-risk breast cancer patients. Neoplasma. 1999;46(3):166-172.
74. Del Peso G, Selgas R, Bajo MA, Fernandez de Castro M, Aguilera A, Cirugeda A, Jimenez C. Serum level of vascular endothelial growth factor is influenced by erythropoietin treatment in peritoneal dialysis patients. Adv Perit Dial. 2000;16:85-89.
75. Kanellis J, Mudge SJ, Fraser S, Katerelos M, Power DA. Redistribution of cytoplasmic VEGF to the basolateral aspect of renal tubular cells in ischemia-reperfusion injury. Kidney Int. 2000 Jun;57(6):2445-2456.
76. Vannay A, Fekete A, Adori C, Toth T, Losonczy G, Laszlo L, Vasarhelyi B, Tulassay T, Szabo A. Divergence of renal vascular endothelial growth factor mRNA expression and protein level in post-ischaemic rat kidneys. Exp Physiol. 2004 Jul;89(4):435-444. [E-pub 2004 May 6.]
77. Moore MA, Hattori K, Heissig B, Shieh JH, Dias S, Crystal RG, Rafii S. Mobilization of endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1, VEGF, and angiopoietin-1. Ann NY Acad Sci. 2001 Jun;938:36-47.
78. Rafii S, Heissig B, Hattori K. Efficient mobilization and recruitment of marrow-derived endothelial and hematopoietic stem cells by adenoviral vectors expressing angiogenic factors. Gene Ther. 2002 May;9(10):631-641.
79. Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, Viviani B, Marinovich M, Cerami A, Coleman TR, Brines M, Ghezzi P. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med. 2003 Sep 15;198(6):971-975.
80. Agnello D, Bigini P, Villa P, Mennini T, Cerami A, Brines ML, Ghezzi P. Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res. 2002 Oct 11;952(1):128-134.
81. Suzuki N, Ohneda O, Takahashi S, Higuchi M, Mukai HY, Nakahata T, Imagawa S, Yamamoto M. Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood. 2002 Oct 1;100(7):2279-2288.
82. Macdougall IC. CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep. 2005 Nov;4(6):436-440.
83. Fiordaliso F, Chimenti S, Staszewsky L, Bai A, Carlo E, Cuccovillo I, Doni M, Mengozzi M, Tonelli R, Ghezzi P, Coleman T, Brines M, Cerami A, Latini R. A non-erythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci USA. 2005 Feb 8;102(6):2046-2051.
84. Savino C, Pedotti R, Baggi F, Ubiali F, Gallo B, Nava S, Bigini P, Barbera S, Fumagalli E, Mennini T, Vezzani A, Rizzi M, Coleman T, Cerami A, Brines M, Ghezzi P, Bianchi R. Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. J Neuroimmunol. 2006 Mar;172(1-2):27-37.